胎儿小于胎龄不同严重程度分期的母体血管生成因子水平
本研究为前瞻性队列研究,纳入604例出生体重小于第10百分位的单胎孕妇,并按严重程度分为SGA及FGR I–IV期,与424例适于胎龄对照比较。结果显示,随胎儿小于胎龄严重程度增加,sFlt-1/PlGF比值异常比例升高;合并子痫前期时该比值异常更显著。但绝对值的重叠较大,提示其用于判断严重程度分期的价值有限。
要点
- sFlt-1/PlGF比值>第95百分位的比例随FGR严重程度增加而升高。
- 合并子痫前期的小于胎龄胎儿中sFlt-1/PlGF比值异常比例显著更高。
- 血管生成因子绝对值在有无子痫前期时均存在较大重叠。
核心结论
- 母体血清血管生成因子水平随胎儿小于胎龄严重程度增加而更趋异常。
- 血管生成因子与严重程度的关联在合并子痫前期时更强。
- 血清绝对值在有无子痫前期时重叠较大,用于判断严重程度分期存在困难。
研究设计与样本
- 前瞻性队列研究,纳入2010年10月至2017年12月单胎妊娠胎儿小于胎龄孕妇604例。
- 对照组为适于胎龄单胎孕妇424例,定义为出生体重≥第10百分位。
- 胎儿小于胎龄定义为出生体重<第10百分位。
主要发现
- sFlt-1/PlGF比值>第95百分位的比例在AGA对照组、SGA组、FGR I期、FGR II期及FGR III–IV期分别为12.7%、7.8%、30.8%、43.8%和62.5%(P=0.0001)。
- 上述各组sFlt-1/PlGF比值中位MoM值分别为0.55(IQR,0.19–2.00)、1.00(IQR,0.31–2.67)、3.03(IQR,0.91–8.20)、3.94(IQR,0.85–9.13)和7.32(IQR,1.44–16.29)(P=0.24)。
- 子痫前期在对照组、SGA组、FGR I期、FGR II期及FGR III–IV期的诊断比例分别为1.9%、3.6%、21.1%、37.5%和50.0%。
- 所有小于胎龄胎儿中,合并子痫前期者与未合并子痫前期者sFlt-1/PlGF比值>第95百分位的比例分别为56.9%与15.4%(P<0.001)。
- 合并子痫前期与未合并子痫前期者sFlt-1/PlGF比值中位MoM分别为8.11(IQR,3.83–27.09)与1.59(IQR,0.52–5.04)(P=0.18)。
关键数值与推荐
- SGA定义为EFW≥第3且<第10百分位且多普勒参数正常。
- FGR I期定义为EFW<第3百分位、持续MCA-PI<第5百分位、UA-PI>第95百分位、CPR<第5百分位或UtA-PI>第95百分位之一。
- FGR II期定义为UA出现舒张末期血流缺失。
- FGR III期定义为UA出现舒张末期血流反向或DV-PI≥第95百分位。
- FGR IV期定义为出现不可放心的胎心监护或DV心房波缺失/反向。
临床怎么用
- sFlt-1/PlGF比值在FGR严重程度评估中的临床应用需结合子痫前期状态解读。
- 由于绝对值重叠较大,不建议单独依赖血管生成因子水平确定胎儿小于胎龄的严重程度分期。
局限性
- FGR II期及FGR III–IV期样本量较小,均为16例。
- sFlt-1/PlGF比值中位MoM组间比较的P值为0.24,绝对值差异未显示统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Angiogenic factors are elevated in fetal growth restriction (FGR), but their clinical value for assessing the severity of FGR and the potential influence of coexisting pre-eclampsia has scarcely been investigated. In this study, our aim was to investigate the profile of maternal angiogenic factors across severity stages of fetal smallness compared with controls, analyzed overall and stratified by the presence or absence of pre-eclampsia, and to investigate whether values of these angiogenic factors, such as placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and the sFlt-1/PlGF ratio, are helpful in determining the severity stage of fetal smallness. METHODS: This was a prospective cohort study of women with a singleton pregnancy diagnosed with fetal smallness (defined as birth weight < 10th centile) (n = 604) between October 2010 and December 2017, compared with a control group of pregnant women with an appropriate-for-gestational-age (AGA) singleton fetus (defined as birth weight ≥ 10th centile) (n = 424). At diagnosis, ultrasound was performed to assess estimated fetal weight (EFW) and Doppler pulsatility indices (PI) of the uterine artery (UtA), umbilical artery (UA), fetal middle cerebral artery (MCA) and ductus venosus (DV), and these parameters were monitored regularly until delivery. Cerebroplacental ratio (CPR) was calculated as MCA-PI/UA-PI. Small fetuses were classified as: small-for-gestational age (SGA) if EFW ≥ 3rd and < 10th centile, with normal Doppler parameters; FGR Stage I if either EFW < 3rd centile, persistent MCA-PI < 5th centile, UA-PI > 95th centile, CPR < 5th centile or UtA-PI > 95th centile; FGR Stage II if there was absent end-diastolic flow in the UA; FGR Stage III if there was reversed end-diastolic flow in the UA or DV-PI ≥ 95th centile; or FGR Stage IV if there was non-reassuring cardiotocography or absent/reversed DV atrial flow. Maternal peripheral venous blood concentrations of PlGF and sFlt-1 were determined using enzyme-linked immunosorbent assay, and the sFlt-1/PlGF ratio was calculated. Linear trend of proportions was tested using the Mantel-Haenszel chi-square test. RESULTS: Among AGA controls (n = 424), SGA (n = 192), FGR Stage I (n = 380), FGR Stage II (n = 16) and FGR Stages III-IV (n = 16) fetuses, the proportion of cases with a sFlt-1/PlGF ratio > 95th centile was 12.7%, 7.8%, 30.8%, 43.8% and 62.5%, respectively (P = 0.0001), and the median multiples of the median (MoM) values for the sFlt-1/PlGF ratio were 0.55 (interquartile range (IQR), 0.19-2.00), 1.00 (IQR, 0.31-2.67), 3.03 (IQR, 0.91-8.20), 3.94 (IQR, 0.85-9.13) and 7.32 (IQR, 1.44-16.29), respectively (P = 0.24). Pre-eclampsia was diagnosed at any time between inclusion and delivery in 1.9% of controls, 3.6% of SGA, 21.1% of FGR Stage I, 37.5% of FGR Stage II and 50.0% of FGR Stages III-IV fetuses. Among all small fetuses with vs without pre-eclampsia, the proportion of pregnancies with sFlt-1/PlGF ratio > 95th centile was 56.9% vs 15.4% (P < 0.001) and the median MoM of the sFlt-1/PlGF ratio was 8.11 (IQR, 3.83-27.09) vs 1.59 (IQR, 0.52-5.04) (P = 0.18). CONCLUSIONS: Serum levels of angiogenic factors became more abnormal as the severity stage of fetal smallness increased. This association with severity was stronger in the presence of pre-eclampsia. However, absolute values of serum levels showed substantial overlap in both the presence and the absence of pre-eclampsia, making their use in determining the severity stage of fetal smallness challenging. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Youssef, Paolucci, Crovetto, et al. Angiogenic factor levels across severity stages of fetal smallness with or without associated pre-eclampsia. Ultrasound Obstet Gynecol. 2026. PMID: 41505741. doi:10.1002/uog.70156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。